Celularity Inc. (CELU)
CELU Stock Price Chart
Explore Celularity Inc. interactive price chart. Choose custom timeframes to analyze CELU price movements and trends.
CELU Company Profile
Discover essential business fundamentals and corporate details for Celularity Inc. (CELU) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Aug 2019
Employees
120.00
Website
https://www.celularity.comCEO
Robert Joseph Hariri
Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
CELU Financial Timeline
Browse a chronological timeline of Celularity Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 4 Dec 2025
Upcoming earnings on 5 Nov 2025
Earnings released on 29 Aug 2025
EPS came in at -$1.02 , while revenue for the quarter reached $5.74M .
Earnings released on 29 Aug 2025
EPS came in at -$0.84 , while revenue for the quarter reached $11.43M .
Earnings released on 8 May 2025
EPS came in at -$0.59 surpassing the estimated -$1.50 by +60.67%, while revenue for the quarter reached $18.13M , beating expectations by +248.69%.
Earnings released on 6 Dec 2024
EPS came in at -$0.73 surpassing the estimated -$1.40 by +47.86%, while revenue for the quarter reached $9.30M , beating expectations by +75.40%.
Earnings released on 7 Nov 2024
EPS came in at -$0.30 surpassing the estimated -$1.40 by +78.57%, while revenue for the quarter reached $12.11M , beating expectations by +152.31%.
Earnings released on 16 Oct 2024
EPS came in at -$1.03 surpassing the estimated -$1.40 by +26.43%, while revenue for the quarter reached $14.68M , beating expectations by +233.66%.
Earnings released on 31 Jul 2024
EPS came in at $0.54 , while revenue for the quarter reached $12.11M , beating expectations by +157.26%.
Stock split effective on 29 Feb 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 2 Jan 2024
EPS came in at -$0.60 falling short of the estimated -$0.04 by -1.57K%, while revenue for the quarter reached $3.79M , missing expectations by -86.09%.
Earnings released on 14 Aug 2023
EPS came in at $3.40 surpassing the estimated -$0.30 by +1.23K%, while revenue for the quarter reached $2.94M , missing expectations by -89.21%.
Earnings released on 22 May 2023
EPS came in at -$2.20 surpassing the estimated -$2.40 by +8.33%, while revenue for the quarter reached $3.94M , missing expectations by -30.23%.
Earnings released on 31 Mar 2023
EPS came in at -$0.03 surpassing the estimated -$0.25 by +88.00%, while revenue for the quarter reached $4.13M , missing expectations by -24.65%.
Earnings released on 10 Nov 2022
EPS came in at $0.30 surpassing the estimated -$2.60 by +111.54%, while revenue for the quarter reached $4.14M , missing expectations by -27.98%.
Earnings released on 9 Aug 2022
EPS came in at $0.30 surpassing the estimated -$2.60 by +111.54%, while revenue for the quarter reached $3.78M , missing expectations by -30.56%.
Earnings released on 16 May 2022
EPS came in at -$4.80 falling short of the estimated -$2.30 by -108.70%, while revenue for the quarter reached $5.94M , beating expectations by +16.60%.
Earnings released on 31 Mar 2022
EPS came in at -$0.30 surpassing the estimated -$2.90 by +89.66%, while revenue for the quarter reached $4.86M , beating expectations by +5.97%.
Earnings released on 12 Nov 2021
EPS came in at $4.00 surpassing the estimated -$2.90 by +237.93%, while revenue for the quarter reached $10.62M , missing expectations by -65.02%.
Earnings released on 16 Aug 2021
EPS came in at -$2.69 falling short of the estimated -$0.16 by -1.58K%, while revenue for the quarter reached $3.20M .
Earnings released on 24 May 2021
EPS came in at $2.48 surpassing the estimated -$0.14 by +1.87K%, while revenue for the quarter reached $2.66M .
Earnings released on 4 Mar 2021
EPS came in at $0.64 , while revenue for the quarter reached $3.24M .
Earnings released on 16 Nov 2020
EPS came in at -$7.56 , while revenue for the quarter reached $3.36M .
CELU Stock Performance
Access detailed CELU performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.